Literature DB >> 19301681

The corneal pocket assay.

Marina Ziche1, Lucia Morbidelli.   

Abstract

Continuous monitoring of neovascular growth in vivo is required for the development and evaluation of drugs acting as suppressors or stimulators of angiogenesis. The cornea assay consists of the placement of an angiogenesis stimulus (tumor tissue, cell suspension, growth factor) into a micropocket produced in the cornea thickness to evoke vascular outgrowth from the peripherally located limbal vasculature. Neovascular development and progression can be modified by the presence of locally released or applied inhibitory factors or by systemically given antiangiogenic drugs. This assay has the advantage over other in vivo assays of measuring new blood vessels only since the cornea is initially avascular. The experimental details of the avascular cornea assay and its advantages and disadvantages in different species are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19301681     DOI: 10.1007/978-1-59745-241-0_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Experimental models to study lymphatic and blood vascular metastasis.

Authors:  Lu Chen; Byron Hann; Lily Wu
Journal:  J Surg Oncol       Date:  2011-05-01       Impact factor: 3.454

2.  A mouse model of the cornea pocket assay for angiogenesis study.

Authors:  Zhongshu Tang; Fan Zhang; Yang Li; Pachiappan Arjunan; Anil Kumar; Chunsik Lee; Xuri Li
Journal:  J Vis Exp       Date:  2011-08-18       Impact factor: 1.355

3.  The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats.

Authors:  Wenru Su; Zhanrong Li; Miaoli Lin; Yongping Li; Zixin He; Chuanbin Wu; Dan Liang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-16       Impact factor: 3.117

4.  Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.

Authors:  Jertta-Riina Sarkanen; Marika Mannerström; Hanna Vuorenpää; Jukka Uotila; Timo Ylikomi; Tuula Heinonen
Journal:  Front Pharmacol       Date:  2011-01-20       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.